金吾财讯 | 礼来(LLY)盘前涨超1%,截至发稿,报786.99美元。消息上,5月6日,据中国药品审评中心(CDE)官网信息,礼来公司提交的Orforglipron胶囊获得临床试验默示许可,拟用于治疗患有高血压的成人肥胖或超重人群。为全球首个口服GLP-1降压药。该研究计划招募487名受试者,研究终点为治疗36周后的血压变化,预计将于2027年9月完成。此外,3月份美国药品进口量激增,因为制药...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.